Using our proprietary PEG hydrogel technology in collaboration with pharmaceutical company partners, Ocular Therapeutix is currently tailoring a first-in-class six month sustained release anti-VEGF hydrogel injection for retinal diseases (see chart below). These therapies would significantly reduce dosing frequency and subsequently reduce doctor visits, and may be able to decrease the likelihood of side effects associated with frequent intravitreal injections.
With Ocular Therapeutix’s tailored sustained release intravitreal injection, the PEG hydrogel and anti-VEGF molecules are injected outside the visual axis using a fine gauge needle. The PEG biocompatible and bioresorbable hydrogel creates a tight meshwork that traps the molecules in solid form, allowing for controlled release and stability. As hydrogel degrades via hydrolysis, mesh size increases and anti-VEGF particles gradually dissolve and diffuse.
Sustained Release in vitro
About Retinal Diseases
Retinal diseases such as age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic macular edema (DME) can be devastating to eyesight, causing central and/or peripheral vision loss. AMD is one of the most common retinal diseases, affecting more than 2 million Americans alone, and is the leading cause of blindness in the United States.1 The global market for anti-VEGF drugs is over $6 billion.2-5
Current therapies for retinal diseases require monthly injections, which have shown to manage the progression of these diseases to prevent further vision loss and in some cases, gain visual acuity. However, these frequent intravitreal injections can increase the risk of infection, retinal detachment, and/or hemorrhage.6